EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results

Pharmaceutical Investing

EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported operating and financial results for its fiscal 2018 third quarter and nine months ended March 31, 2018 and provided a company update. As quoted in the press release: “The acquisition of Icon Bioscience, Inc. and its FDA approved product, DEXYCU™, significantly increases …

As quoted in the press release:

“The acquisition of Icon Bioscience, Inc. and its FDA approved product, DEXYCU™, significantly increases EyePoint Pharmaceuticals’ revenue potential and accelerates our planned transformation to a sustainable growth company,” said Nancy Lurker, President and Chief Executive Officer. “The combination of experienced executives leading our commercial team and the additional capital from EW Healthcare and SWK positions EyePoint to successfully execute on the launch of two new products in the first half of 2019, pending favorable regulatory review of YUTIQ™. In addition, we anticipate the annual revenue potential for DEXYCU to be $150 – $200 million by the end of the third year on the market.”

Click here to read the full press release.

acquisition company update fda fda-approved financial results ophthalmic Pharmaceutical Investing